Omeprazole (A2845): Technical Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a highly selective H+,K+-ATPase inhibitor used to model gastric acid secretion and antiulcer activity in laboratory research. By targeting the proton pump mechanism in parietal cells, Omeprazole enables researchers to dissect pathways involved in gastric acid-related disorders and evaluate antiulcer strategies in preclinical settings. Its well-characterized inhibition profile and purity make it indispensable for studies requiring precision in quantifying acid secretion, antiulcer drug screening, or generating peptic ulcer disease models. However, Omeprazole (A2845) is strictly for scientific research and is not intended for clinical, diagnostic, or non-gastric protocols (product information).

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value: IC50 = 5.8 μM
  Applicability: Use as a reference inhibitor in assays quantifying ATPase activity or gastric acid secretion.
  Rationale: The defined IC50 supports dose-response and mechanistic studies.
  Source type: Product dossier
• Assay: Histamine-induced acid formation inhibition
  Value: IC50 = 0.16 μM
  Applicability: Suitable for protocols modeling histamine-stimulated acid secretion in parietal cells or tissue explants.
  Rationale: Enables sensitive detection of antiulcer effects.
  Source type: Product dossier
• Assay: Compound solubility
  Value: ≥17.27 mg/mL in DMSO; insoluble in water and ethanol
  Applicability: Prepare stock solutions in DMSO only. Avoid protocols requiring aqueous or ethanol solubility.
  Rationale: Ensures reproducible dosing and avoids precipitation or loss of activity.
  Source type: Product dossier
• Assay: Storage and handling
  Value: Store solid at -20°C; avoid long-term storage of solutions
  Applicability: Maintain compound stability for batch-to-batch reproducibility.
  Rationale: Omeprazole is sensitive to moisture and prolonged solution storage.
  Source type: Product dossier

Workflow Setup and QC Checklist

To achieve consistent results in gastric acid secretion research and antiulcer activity studies, follow these workflow guidelines:

• Stock Solution Preparation: Dissolve Omeprazole (A2845) directly in DMSO to a concentration appropriate for your assay (e.g., 10–20 mM). Avoid using water or ethanol due to insolubility (Omeprazole).
• Aliquoting and Storage: Store solid compound at -20°C. Prepare small aliquots to minimize freeze-thaw cycles. Do not retain diluted DMSO solutions longer than a single experiment to prevent degradation.
• Assay Controls: Include vehicle (DMSO) controls in all protocols. For quantitative inhibition studies, apply a range of concentrations to generate a full dose-response curve.
• Quality Control: Verify compound integrity (purity ~98%) upon receipt and before each use. If precipitation or color change is observed in DMSO, prepare a fresh stock.
• Shipping Considerations: Omeprazole should be shipped on blue ice. Confirm package condition and temperature upon arrival, particularly for small molecule shipments.
• Compatibility: Use with established gastric acid secretion models, such as isolated parietal cells, gastric glands, or in vivo rodent models. Refer to related protocols in "Omeprazole (A2845): Lab Guidance for H+,K+-ATPase Inhibition" for stepwise setup.

Common Failure Modes and Fixes

• Solubility Issues: Precipitation or incomplete dissolution occurs if attempting to dissolve in aqueous or ethanol-based buffers. Fix: Use DMSO exclusively as the solvent for stock preparation. Warm gently if necessary, but do not exceed 37°C.
• Loss of Activity: Prolonged storage of Omeprazole in DMSO or repeated freeze-thaw cycles can lead to reduced potency. Fix: Prepare fresh working solutions from solid aliquots for each experiment and avoid repeated thawing.
• Assay Interference: High DMSO concentrations can affect cell viability or assay readouts. Fix: Dilute DMSO stocks so that final solvent concentration does not exceed tolerable limits for your system (typically ≤0.1%).
• Batch Variability: Differences in assay performance may arise from inconsistent handling or storage. Fix: Standardize QC checks (purity, solubility, color) and document batch numbers in all records.

For additional troubleshooting and comparative workflow analysis, see "3-(quinolin-4-ylmethylamino) Thiophene-2-Carboxamide: Advanced Protocols", which details actionable protocols and troubleshooting strategies for gastric acid secretion assays.

Scope and Limitations

• Intended Use: Omeprazole (A2845) is validated for scientific research involving gastric acid secretion, antiulcer activity, and proton pump inhibition. It is not for clinical diagnostics, therapeutic applications, or protocols outside the gastric axis.
• Solubility Constraints: The compound cannot be used in workflows requiring aqueous or ethanol-based solutions. Protocols must be adapted to DMSO solubility.
• Stability: Only the solid form is suitable for long-term storage. DMSO solutions must be prepared fresh for each use to avoid degradation.
• Analytical Boundaries: Product parameters are drawn from the supplier's dossier and validated internal QC; no additional peer-reviewed quantitative outcomes are available for this specific SKU.

Conclusion

Omeprazole (A2845) delivers focused, reproducible inhibition of H+,K+-ATPase, streamlining experimental design in gastric acid secretion and antiulcer activity studies. By observing recommended solubility, storage, and handling workflows, researchers can minimize variability and maximize assay reliability. For standardized protocols and further troubleshooting, consult related internal resources. For detailed product specifications and ordering, refer to the Omeprazole product page.